ArticleFrontiers in bioengineering and biotechnology2025
Biofabrication of 3D-printed, pre-cross-linked alginate dialdehyde-gelatin (ADA-GEL) scaffolds for an
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascularized models mimicking tumor pathophysiology to investigate tumor characteristics are of high interest. The arteriovenous loop (AVL) model is an established method to vitalize bioengineered tissue grafts. In this model, an artificial vascular axis serves as the only connection between the living organism and the biomaterial. The objective of this study was to establish a three-dimensional (3D) printed, functional scaffold design for the AVL rodent model, in which human melanoma cells, derived from lymph node metastasis, are embedded in pre-cross-linked alginate dialdehyde-gelatin (ADA-GEL) and implanted in rats (N = 10) for 4 weeks. Bioink scaffolds were 3D-printed in two different shapes (n = 5), designed specifically for the AVL model's isolation chamber. Before implantation, the swelling behavior of the biofabricates was analyzed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.